Bispecific antibody therapeutic - Genmab/Traverse Biotech
Alternative Names: TB-Bs1Latest Information Update: 29 Oct 2024
At a glance
- Originator Genmab
- Developer Traverse Biotech
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer